Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019;62(4):218-224.
doi: 10.1159/000499539. Epub 2019 May 27.

Update on Screening for Sight-Threatening Diabetic Retinopathy

Peter H Scanlon  1   2   3   4
Affiliations
Review

Update on Screening for Sight-Threatening Diabetic Retinopathy

Peter H Scanlon. Ophthalmic Res. 2019.

Abstract

Purpose: The aim of this article was to describe recent advances in the use of new technology in diabetic retinopathy screening by looking at studies that assessed the effectiveness and cost-effectiveness of these technologies.

Methods: The author conducts an ongoing search for articles relating to screening or management of diabetic retinopathy utilising Zetoc with keywords and contents page lists from relevant journals.

Results: The areas discussed in this article are reference standards, alternatives to digital photography, area of retina covered by the screening method, size of the device and hand-held cameras, mydriasis versus non-mydriasis or a combination, measurement of distance visual acuity, grading of images, use of automated grading analysis and cost-effectiveness of the new technologies.

Conclusions: There have been many recent advances in technology that may be adopted in the future by screening programmes for sight-threatening diabetic retinopathy but each device will need to demonstrate effectiveness and cost-effectiveness before more widespread adoption.

Keywords: Imaging; Retinal screening; Retinopathy; Sight-threatening diabetic retinopathy; Visual loss.

PubMed Disclaimer

Conflict of interest statement

I have attended Advisory Boards for Pfizer, Allergan, Roche, Bayer and Boehringer.

My department has received Educational, Research and Audit Grants from Allergan, Pfizer, Novartis, Boehringer and Bayer in the last 10 years.

References

    1. Wilson J, Jungner G. Public Health Papers 34. Public Health Papers. Geneva: WHO; 1968. The principles and practice of screening for disease.
    1. Scanlon P. London: UCL; 2005. An evaluation of the effectiveness and cost-effectiveness of screening for diabetic retinopathy by digital imaging photography and technician ophthalmoscopy and the subsequent change in activity, workload and costs of new diabetic ophthalmology referrals.
    1. Zheng Y, He M, Congdon N. The worldwide epidemic of diabetic retinopathy. Indian J Ophthalmol. 2012 Sep-Oct;60((5)):428–31. - PMC - PubMed
    1. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Meta-Analysis for Eye Disease (META-EYE) Study Group Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012 Mar;35((3)):556–64. - PMC - PubMed
    1. IDF. International Diabetes Federation. IDF Diabetes Atlas Brussels, Belgium 2013 [16/04/2014]. 6th edition:[Available from: http://www.idf.org/diabetesatlas